Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

Elinore F. McCance-Katz, David E. Moody, Patrick F. Smith, Gene D. Morse, Gerald Friedland, Patricia Pade, Jennifer Baker, Anika Alvanzo, Peter Jatlow, Petrie M. Rainey

Research output: Contribution to journalArticle

Abstract

We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone- maintained, human immunodeficiency virus (HIV)-negative volunteers (n = 10 per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants (n = 15 per PI). Administration of RTV, but not of NFV or LPV/ R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume43
Issue numberSUPPL. 4
DOIs
StatePublished - Dec 15 2006
Externally publishedYes

Fingerprint

Nelfinavir
Lopinavir
Ritonavir
Buprenorphine
Protease Inhibitors
Opiate Alkaloids
Opioid Analgesics
Pharmacokinetics
HIV
Social Adjustment
Substance Withdrawal Syndrome
Virus Diseases
Drug Interactions
Prescriptions
Volunteers
Healthy Volunteers
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

McCance-Katz, E. F., Moody, D. E., Smith, P. F., Morse, G. D., Friedland, G., Pade, P., ... Rainey, P. M. (2006). Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clinical Infectious Diseases, 43(SUPPL. 4). https://doi.org/10.1086/508188

Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. / McCance-Katz, Elinore F.; Moody, David E.; Smith, Patrick F.; Morse, Gene D.; Friedland, Gerald; Pade, Patricia; Baker, Jennifer; Alvanzo, Anika; Jatlow, Peter; Rainey, Petrie M.

In: Clinical Infectious Diseases, Vol. 43, No. SUPPL. 4, 15.12.2006.

Research output: Contribution to journalArticle

McCance-Katz, EF, Moody, DE, Smith, PF, Morse, GD, Friedland, G, Pade, P, Baker, J, Alvanzo, A, Jatlow, P & Rainey, PM 2006, 'Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir', Clinical Infectious Diseases, vol. 43, no. SUPPL. 4. https://doi.org/10.1086/508188
McCance-Katz, Elinore F. ; Moody, David E. ; Smith, Patrick F. ; Morse, Gene D. ; Friedland, Gerald ; Pade, Patricia ; Baker, Jennifer ; Alvanzo, Anika ; Jatlow, Peter ; Rainey, Petrie M. / Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. In: Clinical Infectious Diseases. 2006 ; Vol. 43, No. SUPPL. 4.
@article{cf7e5b908539476a9a9daf862a03c067,
title = "Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir",
abstract = "We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone- maintained, human immunodeficiency virus (HIV)-negative volunteers (n = 10 per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants (n = 15 per PI). Administration of RTV, but not of NFV or LPV/ R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease.",
author = "McCance-Katz, {Elinore F.} and Moody, {David E.} and Smith, {Patrick F.} and Morse, {Gene D.} and Gerald Friedland and Patricia Pade and Jennifer Baker and Anika Alvanzo and Peter Jatlow and Rainey, {Petrie M.}",
year = "2006",
month = "12",
day = "15",
doi = "10.1086/508188",
language = "English (US)",
volume = "43",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir

AU - McCance-Katz, Elinore F.

AU - Moody, David E.

AU - Smith, Patrick F.

AU - Morse, Gene D.

AU - Friedland, Gerald

AU - Pade, Patricia

AU - Baker, Jennifer

AU - Alvanzo, Anika

AU - Jatlow, Peter

AU - Rainey, Petrie M.

PY - 2006/12/15

Y1 - 2006/12/15

N2 - We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone- maintained, human immunodeficiency virus (HIV)-negative volunteers (n = 10 per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants (n = 15 per PI). Administration of RTV, but not of NFV or LPV/ R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease.

AB - We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone- maintained, human immunodeficiency virus (HIV)-negative volunteers (n = 10 per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants (n = 15 per PI). Administration of RTV, but not of NFV or LPV/ R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease.

UR - http://www.scopus.com/inward/record.url?scp=33845416796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845416796&partnerID=8YFLogxK

U2 - 10.1086/508188

DO - 10.1086/508188

M3 - Article

C2 - 17109310

AN - SCOPUS:33845416796

VL - 43

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 4

ER -